Credit: AlphaMed Press
Durham, NC -Tomohiro Nishijima, M.D., was awarded The Oncologist‘s 2nd Annual Young Investigator Award for his research on how the chemotherapy toxicity risk score may assist doctors in making treatment decisions for older patients. The Oncologist journal established this award to foster advancements in the field of oncology by honoring a young researcher who is principal author of a high-impact article with the greatest potential to improve patient outcomes.
In his winning paper, Dr. Nishijima and his team conducted a prospective observational study of older adults with advanced solid tumors receiving first-line chemotherapy. They estimated the level of agreement in treatment decisions, standard or reduced intensity, between the clinical judgment and the risk score and also compared toxicity outcomes between concordant and discordant treatment decisions.
In pursuing a career as a clinical investigator in geriatric oncology, Dr. Nishijima focuses on refining treatment selection for older adults with cancer. He is particularly interested in how to optimize treatment for understudied and high-risk populations of older patients and how to approach this question through better assessment of the risk for treatment-related toxicity.
Dr. Nishijima currently holds the post of chief of geriatric oncology at NHO Kyushu Cancer Center in Fukuoka, Japan, and as adjunct research assistant professor in the hematology-oncology division at the University of North Carolina (UNC), Chapel Hill.
“In my many years of mentoring oncology fellows, Tomo stands out as among the most productive and innovative,” said Dr. Hyman Muss, Geriatric Oncology section editor for The Oncologist. “As a testimony to his academic and clinical expertise he was appointed right from his fellowship to the faculty of the Kyushu Cancer Center in Fukuoka, Japan, to lead one of Japan’s first Geriatric Oncology programs.”
Learn more about Dr. Nishijima or read the winning paper Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors.
About The Oncologist: Now in its 25th year, this internationally peer-reviewed journal focuses on clear and concise interpretation addressing the multimodality diagnosis, treatment, and quality of life of the cancer patient. Each issue is meant to impact the practice of oncology and to facilitate significant communication in the introduction of new medical treatments and technologies. The Oncologist is the official journal of the Society for Translational Oncology (STO).
About AlphaMed Press: Established in 1983, AlphaMed Press, with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. The Oncologist® (http://www.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.